Colorectal cancer refers to a cancer type that starts in the colon or the rectum, and begins on the inner lining of colon or rectum known as polyp. The type of polyp known as adenomatous polyps are more likely to turn into cancer and are termed as precancerous conditions. The symptoms include rectal bleeding, change in bowel habit, abdominal discomfort, weakness or fatigue and weight loss. According to National Institutes of Health (NIH), around 8% of all new cases of cancers are of colorectal cancer, in the U.S. Also, according to the American Cancer Society (ACS), around 95,520 new cases of colon cancer and 39,910 new cases of rectal cancer have been reported in the U.S., in 2017.
The treatment options for colorectal cancer include immunotherapy, chemotherapy and targeted therapy. Many of the immunotherapy and targeted therapy drugs are also under trial such as Pembrolizumab, Nivolumab, Ipilimumab, Durvalumab, Tremelimumab, Atezolizumab and Varlilumab.
Some of the companies having drugs in pipeline for colorectal cancer are Eisai Co. Ltd., F. Hoffmann-La Roche AG, Targovax and Precision Biologics.
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licencing, grants, technology and others.